News
Anida Pharma announces that FDA has granted orphan drug status to AP-001 for the treatment of neurotrophic keratopathy
Cambridge, Massachusetts, January, 3, 2025 --- Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for vision loss, today...
Anida Pharma announces positive Pre-IND meeting with the FDA to set the path for clinical development of AP-001 for the treatment of retinopathy of prematurity
Cambridge, Massachusetts, June, 04, 2024 --- Anida Pharma, a biopharmaceutical company developing first-in-class treatments for vision loss, today announced the...
Anida Pharma announces European Orphan Drug Designation for AP-001
Cambridge, Massachusetts, June 21, 2022 --- Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and...
Anida Pharma granted rare pediatric disease designation for AP-001 for the prevention of retinopathy of prematurity (ROP)
Cambridge, Massachusetts, March 31, 2020 --- Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and...
Anida Pharma announces that FDA has granted AP-001 as a drug “for Rare Pediatric Disease” for the treatment of retinopathy of prematurity
Cambridge, Massachusetts, August, 31, 2020 --- Anida Pharma, a biopharmaceutical company developing ground-breaking treatments for vision loss, today announced that the...
Anida Pharma announces US Orphan Drug Designation for AP-001
Cambridge, Massachusetts, March 31, 2020 --- Anida Pharma, a preclinical stage biopharmaceutical company developing first-in-class treatments for the prevention and...